Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes

Bibliography

• VANE JR, BOTTING RM: The mechanism of action of aspirin. Thromb. Res. (2003) 110(5–6):255–258.
   Google Scholar
• THEROUX P, OUIMET H, MCCANS J et al. : Aspirin, heparin or both to treat acute unstable angina. N. Engl. J. Med. (1988) 319:1105–1111.
   PubMed Web of Science ®Google Scholar
• RESEARCH GROUP ON INSTABILITY IN CORONARY ARTERY DISEASE IN SOUTHEAST SWEDEN (RISC): Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk of myocardial infarction, occurrence of severe angina and the need for revascularisation. J. Am. Coll. Cardiol. (1991) 18:1587–1593.
   PubMed Web of Science ®Google Scholar
• LEON MB, BAIM DS, POPMA JJ et al. ; for the STENT ANTICOAGULATION RESTENOSIS STUDY INVESTIGATORS: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med. (1998) 339(23):1665–1671.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALISTS’ COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   PubMed Web of Science ®Google Scholar
• LAU WC, GURBEL PA, WATKINS PB et al. : Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. (2004): 109:166–171.
   PubMed Web of Science ®Google Scholar
• PETERS RJ, MEHTA SR, FOX KA et al. ; for the CURE STUDY INVESTIGATORS: Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. (2003) 108(14):1682–1687.
   PubMed Web of Science ®Google Scholar
• COUKELL AJ, MARKHAM A: Clopidogrel. Drugs (1997) 54(5):745–750.
   PubMed Web of Science ®Google Scholar
• GEIGER J, BIRCH J, HONIG-LIEDL P et al. : Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2007–2011.
   PubMed Web of Science ®Google Scholar
• SAVCIC M, HAUERT J, BACHMANN F et al. : Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. (1999) 25(Suppl. 2):15–19.
   PubMedGoogle Scholar
• YUSUF S, ZHAO F, MEHTA SR et al. : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494–502.
   PubMed Web of Science ®Google Scholar
• SCHOMIG A, SCHMITT C, DIBRA A et al. : One year outcomes with abciximab versus placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur. Heart J. (2005) 26(14):1379–1384.
   PubMed Web of Science ®Google Scholar
• MEHILLI J, KASTRATI A, SCHUHLEN H et al. : Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 110(24):3627–3635.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• CHU MW, WILSON SR, NOVICK RJ et al. : Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann. Thorac. Surg. (2004) 78(5):1536–1541.
   PubMed Web of Science ®Google Scholar
• NGUYEN TA, DIODATI JG, PHARAND C: Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. (2005) 45(8):1157–1164.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, HIATT BL et al. : Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107(23):2908–2913.
   PubMed Web of Science ®Google Scholar
• JNEID H, BHATT DL, CORTI R et al. : Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch. Intern. Med. (2003) 163(10):1145–1153.
   PubMed Web of Science ®Google Scholar
• MOBLEY JE, BRESEE SJ, WORTHAM DC et al. : Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. (2004) 93(4):456–458.
   PubMed Web of Science ®Google Scholar
• MATETZKY S, SHENKMAN B, GUETTA V et al. : Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109(25):3171–3175.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke (2000) 31(7):1779–1784.
   PubMed Web of Science ®Google Scholar
• PHILLIPS DR, CHARO IF, PARISE LV et al. : The platelet membrane glycoprotein IIb-IIIa complex. Blood (1988) 71(4):831–843.
   PubMed Web of Science ®Google Scholar
• WAGNER CL, MASCELLI MA, NEBLOCK DS et al. Analysis of G PIIb/ IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:9907–9914.
   Google Scholar
• BATES ER: Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin. Thromb. Hemost. (1997) 23(6):575–581.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS, KLEM J, FERNANDES LS et al. : Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am. Heart. J. (2002) 143(4):585–593.
   PubMed Web of Science ®Google Scholar
• IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (1997) 349(9063):1422–1428.
   PubMed Web of Science ®Google Scholar
• PRISM-PLUS INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. (1998) 338(21):1488–1497.
   PubMed Web of Science ®Google Scholar
• RESTORE INVESTIGATORS: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation (1997) 96(5):1445–1453.
   PubMed Web of Science ®Google Scholar
• CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429–1435.
   PubMed Web of Science ®Google Scholar
• EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. (1994) 330(14):956–961.
   PubMed Web of Science ®Google Scholar
• EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. (1997) 336(24):1689–1696.
   PubMed Web of Science ®Google Scholar
• ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356(9247):2037–2044.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, MEHILLI J, SCHUHLEN H et al. : A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. (2004) 350:232–238.
   PubMed Web of Science ®Google Scholar
• DALBY M, MONTALESCOT G, BAL DIT SOLLIER C et al. : Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol. (2004) 43(2):162–168.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, ZAMAN KA et al. : Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation (2005) 111:1153–1159.
   PubMed Web of Science ®Google Scholar
• BRENER SJ, ELLIS SG, SCHNEIDER J et al. : Frequency and long-term impact of myonecrosis after coronary stenting. Eur. Heart. J. (2002) 23(11):869–876.
   PubMed Web of Science ®Google Scholar
• IOANNIDIS JP, KARVOUNI E, KATRITSIS DG: Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J. Am. Coll. Cardiol. (2003) 42(8):1406–1411.
   PubMed Web of Science ®Google Scholar
• SILBER S, ALBERTSSON P, AVILES FF et al. : Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. (2005) 26(8):804–847.
   PubMed Web of Science ®Google Scholar
• COLLER BS, SCUDDER LE: Inhibition of dog platelet function by in vivo infusion of F(ab’)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood (1985) 66(6):1456–1459.
   PubMed Web of Science ®Google Scholar
• IBBOTSON T, MCGAVIN JK, GOA KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs (2003) 63(11):1121–1163.
   PubMed Web of Science ®Google Scholar
• SCHROR K, WEBER AA: Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis (2003) 15(2):71–80.
   PubMed Web of Science ®Google Scholar
• EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet (1998) 352(9122):87–92.
   PubMed Web of Science ®Google Scholar
• PRISM INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. (1998) 338(21):1498–1505.
   PubMedGoogle Scholar
• TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al. : Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. (2001) 344(25):1888–1894.
   PubMed Web of Science ®Google Scholar
• ROFFI M, MOLITERNO DJ, MEIER B et al. : Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year followup. Circulation (2002) 105(23):2730–2736.
   PubMed Web of Science ®Google Scholar
• GRETLER DD, GUERCIOLINI R, WILLIAMS PJ: Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. (2004) 26(3):390–398.
   PubMed Web of Science ®Google Scholar
• O’fSHEA JC, BULLER CE, CANTOR WJ et al. : Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA (2002) 287(5):618–621.
   PubMed Web of Science ®Google Scholar
• PURSUIT INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. (1998) 339(7):436–443.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, BITTL JA, HARRINGTON RA et al. : Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 289(7):853–863.
   PubMed Web of Science ®Google Scholar
• BATCHELOR WB, TOLLESON TR, HUANG Y et al. : Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of platelet aggregation with aggrastat, ReoPro and eptifibatide. Circulation (2002) 106(12):1470–1476.
   PubMed Web of Science ®Google Scholar
• SAUCEDO JF, GARZA L, WOLFORD DC et al. : Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am. J. Cardiol. (2004) 93(10):1279–1282.
   PubMed Web of Science ®Google Scholar
• SAUCEDO JF, LUI HK, GARZA L et al. : Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. J. Thromb. Thrombolysis (2004) 18(2):67–74.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, BRODERICK TM, ROTH EM et al. : Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol. (1999) 84(4):391–395.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al. : ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarctionsummary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Am. Coll. Cardiol. (2002) 40(7):1366–1374.
   PubMed Web of Science ®Google Scholar
• SMITH SC, DOVE JT, JACOBS AK et al. : ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary. J. Am. Coll. Cardiol. (2001) 37(8):2215–2238.
   Google Scholar
• STEINHUBL SR, TALLEY JD, BRADEN GA et al. : Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Integra) multimember study. Circulation (2001) 103:2572–2578.
   PubMed Web of Science ®Google Scholar
• HEESCHEN C, DIMMELER S, HAMM CW et al. ; for the CAPTURE STUDY INVESTIGATORS: Soluble CD40 Ligand in acute coronary syndromes. N. Engl. J. Med. (2003) 348:1104–1111.
   PubMed Web of Science ®Google Scholar
• WELT FG, ROGERS SD, ZHANG X et al. : GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter. Cardiovascular. Intern. (2004) 61(2):185–189.
   PubMed Web of Science ®Google Scholar
• RIOUFOL G, FINET G, GINON I et al. : Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation (2002) 106(7):804–808.
   PubMed Web of Science ®Google Scholar
• AULT KA, CANNON CP, MITCHELL J et al. : Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. (1999) 33:634–639.
   PubMed Web of Science ®Google Scholar
• TRIP MD, CATS VM, VAN CAPELLE FJ et al. : Platelet hyper reactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. (1990) 322:1549–1554.
   PubMed Web of Science ®Google Scholar